Skip Navigation LinksHome > September 2013 - Volume 47 - Issue 8 > Serum HMGB1 as a Diagnostic Marker for Malignant Peritoneal...
Journal of Clinical Gastroenterology:
doi: 10.1097/MCG.0b013e318297fa65
ALIMENTARY TRACT: Original Articles

Serum HMGB1 as a Diagnostic Marker for Malignant Peritoneal Mesothelioma

Tabata, Chiharu MD, PhD*; Kanemura, Shingo MD*; Tabata, Rie MD, PhD; Masachika, Eriko MD*; Shibata, Eisuke MD*; Otsuki, Tai-Ichiro MD*; Nishizaki, Tomoyuki MD, PhD; Nakano, Takashi MD, PhD*

Collapse Box


Background: Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive malignant tumor of mesothelial origin that shows a limited response to cytoreductive surgery along with intraperitoneal chemotherapy. Therefore, early diagnosis of DMPM is very important. Some researchers have previously reported that high-mobility group box 1 (HMGB1) was correlated with pulmonary fibrosis. DMPM involves the malignant transformation of mesothelial cells, which originate from mesenchymal cells, similar to lung fibroblasts. Here, we investigated serum levels of HMGB1 in patients with MPM and compared them with those of a population that had been exposed to asbestos without developing MPM.

Study: The serum concentrations of HMGB1 were measured in 13 DMPM patients and 45 individuals with benign asbestos-related diseases.

Result: We demonstrated that the patients with DMPM had significantly higher serum levels of HMGB1 compared with the population who had been exposed to asbestos but did not develop DMPM.

Conclusion: Our data suggest that serum HMGB1 concentration is a useful serum marker for DMPM.

© 2013 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.